{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:37:04Z","timestamp":1765949824319,"version":"3.48.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Gynecologic cancer is one of the most common malignancies in working-age women. This study aimed to investigate factors associated with period of sick leave after gynecologic cancer treatment in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective cohort study on period of sick leave was conducted among 207 cancer survivors who returned to work at the same workplace. Questionnaires were randomly distributed to patients aged under 65\u00a0years and more than one-year post-treatment. Clinical information was extracted from medical records, and the factors influencing the period of sick leave were analyzed using the Mann\u2013Whitney U test and logistic regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Surgery plus more than six courses of chemotherapy (number (\n                      <jats:italic>n<\/jats:italic>\n                      )\u2009=\u200941, 166.02\u2009\u00b1\u2009146.84\u00a0days) led to a significantly longer period of sick leave than surgery without lymph node dissection (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200964, 31.15\u2009\u00b1\u200930.47\u00a0days), surgery with lymph node dissection (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200941, 55.56\u2009\u00b1\u200985.90\u00a0days), surgery plus less than six courses of chemotherapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921, 72.42\u2009\u00b1\u200956.07\u00a0days), and radiotherapy alone (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921, 58.85\u2009\u00b1\u200984.24\u00a0days) (OR: 2.63, 2.95, 2.67, and 2.08; 95% CI: 7.71\u201354.59, 18.17\u201392.94, 18.22\u2013126.63, and 2.38\u2013115.33;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009, and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041). gynecologic cancer survivors who experienced adverse effects after treatment had a significantly longer period of sick leave (OR: 8.50; CI: 52.98\u201384.98;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In univariate and multivariate analyses, patients who received surgery plus more than six courses of chemotherapy were most involved in long period of sick leave than other factors (OR: 11.20, and 16.997; CI: 4.86\u201325.08, and 5.51\u201352.35;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001, and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with gynecologic cancer requiring long-term treatment required the most time to return to work.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-025-10116-5","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:19:46Z","timestamp":1763533186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with period of sick leave after gynecologic cancer treatment: a prospective cohort study"],"prefix":"10.1007","volume":"33","author":[{"given":"Yoshinori","family":"Tani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanako","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Ida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Haraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Masuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"10116_CR1","unstructured":"Ministry of Health, Labour and Welfare (2022) Tokyo: cancer statistics. Cancer Information Service, National Cancer Center, Japan. [Summary of latest cancer statistics].\u00a0Foundation for Promotion of Cancer Research, pp 1\u201368"},{"key":"10116_CR2","doi-asserted-by":"publisher","unstructured":"Yoshino K, Kutita T, Takahashi F, Nagase S, Board members of the 2022 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology (2023) Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2020 and Annual Treatment Report for 2015. J Obstet Gynaecol Res 49:2584\u20132592. https:\/\/doi.org\/10.1111\/jog.15767","DOI":"10.1111\/jog.15767"},{"key":"10116_CR3","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2017.28.e32","volume":"28","author":"W Yamagami","year":"2017","unstructured":"Yamagami W, Nagase S, Takahashi F et al (2017) Clinical statistics of gynecologic cancers in Japan. J Gynecol Oncol 28:e32. https:\/\/doi.org\/10.3802\/jgo.2017.28.e32","journal-title":"J Gynecol Oncol"},{"key":"10116_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16081461","volume":"16","author":"A Ota","year":"2019","unstructured":"Ota A, Fujisawa A, Kawada K, Yatsuya H (2019) Recent status and methodological quality of return-to-work rates of cancer patients reported in Japan: a systematic review. Int J Environ Res Public Health 16:1461. https:\/\/doi.org\/10.3390\/ijerph16081461","journal-title":"Int J Environ Res Public Health"},{"key":"10116_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2627-0","volume":"16","author":"K Nakamura","year":"2016","unstructured":"Nakamura K, Masuyama H, Nishida T et al (2016) Return to work after cancer treatment of gynecologic cancer in Japan. BMC Cancer 16:558. https:\/\/doi.org\/10.1186\/s12885-016-2627-0","journal-title":"BMC Cancer"},{"key":"10116_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/jjco\/hyad159","volume":"54","author":"K Nakamura","year":"2024","unstructured":"Nakamura K, Matsuoka H, Kubo K et al (2024) Not taking sick leave for gynecologic cancer treatment is negatively associated with returning to the same workplace. Jpn J Clin Oncol 54:292\u2013296. https:\/\/doi.org\/10.1093\/jjco\/hyad159","journal-title":"Jpn J Clin Oncol"},{"key":"10116_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.critrevonc.2010.01.004","volume":"77","author":"A Mehnert","year":"2011","unstructured":"Mehnert A (2011) Employment and work-related issues in cancer survivors. Crit Rev Oncol Hematol 77:109\u2013130. https:\/\/doi.org\/10.1016\/j.critrevonc.2010.01.004","journal-title":"Crit Rev Oncol Hematol"},{"key":"10116_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s11764-015-0478-3","volume":"10","author":"M Endo","year":"2016","unstructured":"Endo M, Haruyama Y, Takahashi M et al (2016) Returning to work after sick leave due to cancer: a 365-day cohort study of Japanese cancer survivors. J Cancer Surviv 10:320\u2013329. https:\/\/doi.org\/10.1007\/s11764-015-0478-3","journal-title":"J Cancer Surviv"},{"key":"10116_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/S12094-010-0474-z","volume":"12","author":"G Guti\u00e9rrez-Guti\u00e9rrez","year":"2010","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez G, Sereno M, Miralles A et al (2010) Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol 12:81\u201391. https:\/\/doi.org\/10.1007\/S12094-010-0474-z","journal-title":"Clin Transl Oncol"},{"key":"10116_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/WCO.0b013e3282f1a06e","volume":"20","author":"G Kannarkat","year":"2007","unstructured":"Kannarkat G, Lasher EE, Schiff D (2007) Neurologic complications of chemotherapy agents. Curr Opin Neurol 20:719\u2013725. https:\/\/doi.org\/10.1097\/WCO.0b013e3282f1a06e","journal-title":"Curr Opin Neurol"},{"key":"10116_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1023\/a:1008345613594","volume":"11","author":"TJ Postma","year":"2000","unstructured":"Postma TJ, Heimans JJ (2000) Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509\u2013513. https:\/\/doi.org\/10.1023\/a:1008345613594","journal-title":"Ann Oncol"},{"key":"10116_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1081\/cnv-120018236","volume":"21","author":"C Visovsky","year":"2003","unstructured":"Visovsky C (2003) Chemotherapy-induced peripheral neuropathy. Cancer Invest 21:439\u2013451. https:\/\/doi.org\/10.1081\/cnv-120018236","journal-title":"Cancer Invest"},{"key":"10116_CR13","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1097\/IGC.0000000000001320","volume":"28","author":"H Matsuoka","year":"2018","unstructured":"Matsuoka H, Nakamura K, Matsubara Y et al (2018) The influence of chemotherapy-induced peripheral neuropathy on quality of life of gynecologic cancer survivors. Int J Gynecol Cancer 28:1394\u20131402. https:\/\/doi.org\/10.1097\/IGC.0000000000001320.","journal-title":"Int J Gynecol Cancer"},{"key":"10116_CR14","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ygyno.2006.03.055","volume":"103","author":"NR Abu-Rustum","year":"2006","unstructured":"Abu-Rustum NR, Alektiar K, Iasonos A et al (2006) The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 103:714\u2013718. https:\/\/doi.org\/10.1016\/j.ygyno.2006.03.055","journal-title":"Gynecol Oncol"},{"key":"10116_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1525-1438.2007.00869.x","volume":"17","author":"T Tanaka","year":"2007","unstructured":"Tanaka T, Ohki N, Kojima A et al (2007) Radiotherapy negates the effect of retroperitoneal nonclosure for prevention of lymphedema of the legs following pelvic lymphadenectomy for gynecological malignancies: an analysis from a questionnaire survey. Int J Gynecol Cancer 17:460\u2013464. https:\/\/doi.org\/10.1111\/j.1525-1438.2007.00869.x","journal-title":"Int J Gynecol Cancer"},{"key":"10116_CR16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/IGC.0b013e3182466950","volume":"22","author":"JH Kim","year":"2012","unstructured":"Kim JH, Choi JH, Ki EY et al (2012) Incidence and risk factors of lower-extremity lymphedema after surgery with or without adjuvant radiotherapy in patients with FIGO stage I to stage IIA cervical cancer. Int J Gynecol Cancer 22:686\u2013691. https:\/\/doi.org\/10.1097\/IGC.0b013e3182466950","journal-title":"Int J Gynecol Cancer"},{"key":"10116_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/IGC.0000000000000840","volume":"27","author":"K Nakamura","year":"2017","unstructured":"Nakamura K, Masuyama H, Ida N et al (2017) Radical hysterectomy plus concurrent chemoradiation\/radiation therapy is negatively associated with return to work in patients with cervical cancer. Int J Gynecol Cancer 27:117\u2013122. https:\/\/doi.org\/10.1097\/IGC.0000000000000840","journal-title":"Int J Gynecol Cancer"},{"key":"10116_CR18","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/cncr.22684","volume":"109","author":"V Beesley","year":"2007","unstructured":"Beesley V, Janda M, Eakin E et al (2007) Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs. Cancer 109:2607\u20132614. https:\/\/doi.org\/10.1002\/cncr.22684","journal-title":"Cancer"},{"key":"10116_CR19","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/pon.1820","volume":"20","author":"CA Roelen","year":"2011","unstructured":"Roelen CA, Koopmans PC, Groothoff JW et al (2011) Sickness absence and full return to work after cancer: 2-year follow-up of register data for different cancer sites. Psychooncology 20:1001\u20131006. https:\/\/doi.org\/10.1002\/pon.1820","journal-title":"Psychooncology"},{"key":"10116_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10926-010-9274-0","volume":"21","author":"CAM Roelen","year":"2011","unstructured":"Roelen CAM, Koopmans PC, Schellart AJM, van der Beek AJ (2011) Resuming work after cancer: a prospective study of occupational register data. J Occup Rehabil 21:431\u2013440. https:\/\/doi.org\/10.1007\/s10926-010-9274-0","journal-title":"J Occup Rehabil"},{"key":"10116_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/ecc.12033","volume":"22","author":"P van Muijen","year":"2013","unstructured":"van Muijen P, Weevers NLEC, Snels IAK et al (2013) Predictors of return to work and employment in cancer survivors: a systematic review. Eur J Cancer Care (Engl) 22:144\u2013160. https:\/\/doi.org\/10.1111\/ecc.12033","journal-title":"Eur J Cancer Care (Engl)"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10116-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-10116-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10116-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:32:26Z","timestamp":1765949546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-10116-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10116"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-10116-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Okayama University Ethics Committee (Ethics Committee number: 2310\u2013033), subject to obtaining patient consent, in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"1087"}}